Eribulin |
Microtubule inhibitor |
II |
12 months to 18 years old |
Recruiting |
Eribulin–irinotecan |
Microtubule inhibitor - cytotoxic |
I–II |
6 months to 17 years old |
Recruiting |
Nab-paclitaxel–gemcitabine |
Microtubule inhibitor - cytotoxic |
II |
12 to 30 years old |
Recruiting |
I |
6 months to 30 years old |
Recruiting |
Nab-paclitaxel |
Microtubule inhibitor |
II |
6 months to 80 years old |
Recruiting |
Trabectedin–irinotecan |
Cytostatic–cytotoxic |
I |
10 years and older |
Not yet recruiting |
SM-88–MPS |
Protein synthesis, multiagent |
II |
12 years and older |
Recruiting |
Ganitumab–chemotherapy |
IGF-1R, cytotoxic/cytostatic |
III |
Up to 50 years old |
Active, not recruiting |
Cabozantinib |
MET |
II |
2 to 30 years old |
Recruiting |
Palbociclib–temozolomide +/− irinotecan |
CDK4/6, multiagent |
I |
2 to 20 years old |
Recruiting |
Palbociclib–ganitumab |
CDK4/6, IGF-1R |
II |
12 to 50 years old |
Recruiting |
Pazopanib–irinotecan–temozolomide |
Multityrosine kinase inhibitor, multiagent |
I |
6 to 30 years old |
Active, not recruiting |
Olaparib–temozolomide +/− irinotecan |
PARP, multiagent |
I |
16 years and older |
Recruiting |
Niraparib–irinotecan–temozolomide |
PARP, multiagent |
I |
13 years and older |
Recruiting |
INCB059872 |
LSD-1 |
Ib |
12 years and older |
Recruiting |
Seclidemstat |
LSD-1 |
I |
12 years and older |
Recruiting |
Abemaciclib–temozolomide/irinotecan |
CDK4/6, multiagent |
I |
Up to 18 years old |
Recruiting |
Selinexor–ixazomib |
CRM1, PSMB5 |
I |
14 years and older |
Not yet recruiting |
Vorinostat–chemotherapy |
Histone deacetylaces, multiagent |
I |
1 to 30 years old |
Recruiting |
Ivosidenib |
IDH-1 |
II |
1 to 21 years old |
Not yet recruiting |
Vigil–temozolomide–irinotecan |
Biological, multiagent |
III |
2 years and older |
Active, not recruiting |
CAR-T cells |
Biological |
I – II |
18 to 65 years old |
Recruiting |
EGFR806 CAR T cell immunotherapy |
Biological |
I |
1 to 26 years old |
Recruiting |
C7R-GD2.CART cells |
Biological |
I |
1 to 74 years old |
Recruiting |
pbi-shRNA™ EWS/FLI1 Type 1 LPX |
Biological |
I |
8 years and older |
Active, not recruiting |
CLR 131 |
Radioionated drug |
I |
2 to 21 years old |
Recruiting |